Mar 10, 2020 • 8:05 am EDT Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
Mar 5, 2020 • 8:05 am EST Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
Feb 11, 2020 • 4:01 pm EST Corbus Pharmaceuticals Announces Closing of $46 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Feb 7, 2020 • 9:02 am EST Corbus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Dec 9, 2019 • 8:05 am EST Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
Nov 18, 2019 • 8:17 am EST Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
Nov 12, 2019 • 8:05 am EST Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London
Nov 11, 2019 • 8:05 am EST Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
Nov 7, 2019 • 7:05 am EST Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates